Epic Sciences, Inc.

Epic’s Comprehensive Cancer Profiling approach uses multiple technologies to provide up to three types of analysis all based on a single blood draw. We leverage proven and proprietary CTC capabilities, along with ctDNA and immune-cell analysis. This allows a clearer and more efficient picture for both prostate and breast cancer. Our enrichment-free approach minimizes the risk of CTCs being missed and reveals both genotypic and phenotypic data. By combining CTC technology with ctDNA and immune-cell analysis, we enable a predictive test that is both minimally invasive and highly accurate.

Our clinical solutions, proven by partnerships, help enhance drug development and expedite commercialization with valuable insights into the dynamics of cancer growth and evolution. Comprehensive Cancer Profiling combines our proven and proprietary CTC capabilities, along with ctDNA and immune-cell analysis to create a more complete picture for discovering new insights into the dynamics of cancer growth. We use our insights to develop clinical solutions that enhance drug development for proven clinical utility.
... More Info Less Info